The Experts below are selected from a list of 43053 Experts worldwide ranked by ideXlab platform
Walter Vincken - One of the best experts on this subject based on the ideXlab platform.
-
Forced vital capacity and Forced Expiratory Volume in six seconds as predictors of reduced total lung capacity
European Respiratory Journal, 2008Co-Authors: Jan Vandevoorde, L. Broekaert, Jan Kartounian, Dirk Devroey, Daniel Schuermans, Sylvia Verbanck, Walter VinckenAbstract:The present study aims to derive guidelines that identify patients for whom spirometry can reliably predict a reduced total lung capacity (TLC). A total of 12,693 lung function tests were analysed on Caucasian subjects, aged 18–70 yrs. Restriction was defined as a reduced TLC. Lower limits of normal (LLN) for TLC were obtained from the European Respiratory Society recommended reference equations. Reference equations from the National Health and Nutrition Examination Survey III were used for Forced vital capacity (FVC) and Forced Expiratory Volume in six seconds (FEV6). The performance of FVC and FEV6 to predict the presence of restriction was studied as follows: 1) using two-by-two (2×2) tables; and 2) by logistic regression analysis. Both analyses were performed in obstructive (defined as Forced Expiratory Volume in one second (FEV1)/FVC or FEV1/FEV6
-
Forced vital capacity and Forced Expiratory Volume in six seconds as predictors of reduced total lung capacity
European Respiratory Journal, 2008Co-Authors: Jan Vandevoorde, L. Broekaert, Jan Kartounian, Dirk Devroey, Daniel Schuermans, Sylvia Verbanck, Walter VinckenAbstract:The present study aims to derive guidelines that identify patients for whom spirometry can reliably predict a reduced total lung capacity (TLC). A total of 12,693 lung function tests were analysed on Caucasian subjects, aged 18-70 yrs. Restriction was defined as a reduced TLC. Lower limits of normal (LLN) for TLC were obtained from the European Respiratory Society recommended reference equations. Reference equations from the National Health and Nutrition Examination Survey III were used for Forced vital capacity (FVC) and Forced Expiratory Volume in six seconds (FEV(6)). The performance of FVC and FEV(6) to predict the presence of restriction was studied as follows: 1) using two-by-two (2x2) tables; and 2) by logistic regression analysis. Both analyses were performed in obstructive (defined as Forced Expiratory Volume in one second (FEV(1))/FVC or FEV(1)/FEV(6) 100% pred (males) or >85% pred (females). In obstructive patients, spirometry cannot reliably diagnose a concomitant restrictive defect, but it can rule out restriction for patients with Forced vital capacity or Forced Expiratory Volume in six seconds >85% pred (males) or >70% pred (females).
-
Forced vital capacity and Forced Expiratory Volume in six seconds as predictors of reduced total lung capacity
European Respiratory Journal, 2008Co-Authors: Jan Vandevoorde, L. Broekaert, Jan Kartounian, Dirk Devroey, Daniel Schuermans, Sylvia Verbanck, Walter VinckenAbstract:The present study aims to derive guidelines that identify patients for whom spirometry can reliably predict a reduced total lung capacity (TLC). A total of 12,693 lung function tests were analysed on Caucasian subjects, aged 18–70 yrs. Restriction was defined as a reduced TLC. Lower limits of normal (LLN) for TLC were obtained from the European Respiratory Society recommended reference equations. Reference equations from the National Health and Nutrition Examination Survey III were used for Forced vital capacity (FVC) and Forced Expiratory Volume in six seconds (FEV6). The performance of FVC and FEV6 to predict the presence of restriction was studied as follows: 1) using two-by-two (2×2) tables; and 2) by logistic regression analysis. Both analyses were performed in obstructive (defined as Forced Expiratory Volume in one second (FEV1)/FVC or FEV1/FEV6
Thomas B Edwards - One of the best experts on this subject based on the ideXlab platform.
-
montelukast a once daily leukotriene receptor antagonist in the treatment of chronic asthma a multicenter randomized double blind trial
JAMA Internal Medicine, 1998Co-Authors: Theodore F Reiss, Paul Chervinsky, Robert J Dockhorn, Sumiko Shingo, Beth C Seidenberg, Thomas B EdwardsAbstract:Objectives To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more. Design Randomized, multicenter, double-blind, placebo-controlled, parallel-group study. A 2-week, single-blind, placebo run-in period was followed by a 12-week, double-blind treatment period (montelukast sodium, 10 mg, or matching placebo, once daily at bedtime) and a 3-week, double-blind, washout period. Setting/Patients Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a Forced Expiratory Volume in 1 second 50% to 85% of the predicted value, at least a 15% improvement in Forced Expiratory Volume in 1 second (absolute value) after inhaled β-agonist administration, a minimal predefined level of daytime asthma symptoms, and inhaled β-agonist use. Twenty-three percent of the patients used concomitant inhaled corticosteroids. Primary End Points Forced Expiratory Volume in 1 second and daytime asthma symptoms. Results Montelukast improved airway obstruction (Forced Expiratory Volume in 1 second, morning and evening peak Expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" β-agonist use, nocturnal awakenings) ( P P P Conclusions Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.
-
montelukast a once daily leukotriene receptor antagonist in the treatment of chronic asthma a multicenter randomized double blind trial
JAMA Internal Medicine, 1998Co-Authors: Theodore F Reiss, Paul Chervinsky, Robert J Dockhorn, Sumiko Shingo, Beth C Seidenberg, Thomas B EdwardsAbstract:OBJECTIVES: To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more. DESIGN: Randomized, multicenter, double-blind, placebo-controlled, parallel-group study. A 2-week, single-blind, placebo run-in period was followed by a 12-week, double-blind treatment period (montelukast sodium, 10 mg, or matching placebo, once daily at bedtime) and a 3-week, double-blind, washout period. SETTING/PATIENTS: Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a Forced Expiratory Volume in 1 second 50% to 85% of the predicted value, at least a 15% improvement in Forced Expiratory Volume in 1 second (absolute value) after inhaled beta-agonist administration, a minimal predefined level of daytime asthma symptoms, and inhaled beta-agonist use. Twenty-three percent of the patients used concomitant inhaled corticosteroids. PRIMARY END POINTS: Forced Expiratory Volume in 1 second and daytime asthma symptoms. RESULTS: Montelukast improved airway obstruction (Forced Expiratory Volume in 1 second, morning and evening peak Expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" beta-agonist use, nocturnal awakenings) (P<.001 compared with placebo). Montelukast provided near-maximal effect in these end points within the first day of treatment. Tolerance and rebound worsening of asthma did not occur. Montelukast improved outcome end points, including asthma exacerbations, asthma control days (P<.001 compared with placebo), and decreased peripheral blood eosinophil counts (P<.001 compared with placebo). The incidence of adverse events and discontinuations from therapy were similar in the montelukast and placebo groups. CONCLUSIONS: Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.
Jan Vandevoorde - One of the best experts on this subject based on the ideXlab platform.
-
Forced vital capacity and Forced Expiratory Volume in six seconds as predictors of reduced total lung capacity
European Respiratory Journal, 2008Co-Authors: Jan Vandevoorde, L. Broekaert, Jan Kartounian, Dirk Devroey, Daniel Schuermans, Sylvia Verbanck, Walter VinckenAbstract:The present study aims to derive guidelines that identify patients for whom spirometry can reliably predict a reduced total lung capacity (TLC). A total of 12,693 lung function tests were analysed on Caucasian subjects, aged 18–70 yrs. Restriction was defined as a reduced TLC. Lower limits of normal (LLN) for TLC were obtained from the European Respiratory Society recommended reference equations. Reference equations from the National Health and Nutrition Examination Survey III were used for Forced vital capacity (FVC) and Forced Expiratory Volume in six seconds (FEV6). The performance of FVC and FEV6 to predict the presence of restriction was studied as follows: 1) using two-by-two (2×2) tables; and 2) by logistic regression analysis. Both analyses were performed in obstructive (defined as Forced Expiratory Volume in one second (FEV1)/FVC or FEV1/FEV6
-
Forced vital capacity and Forced Expiratory Volume in six seconds as predictors of reduced total lung capacity
European Respiratory Journal, 2008Co-Authors: Jan Vandevoorde, L. Broekaert, Jan Kartounian, Dirk Devroey, Daniel Schuermans, Sylvia Verbanck, Walter VinckenAbstract:The present study aims to derive guidelines that identify patients for whom spirometry can reliably predict a reduced total lung capacity (TLC). A total of 12,693 lung function tests were analysed on Caucasian subjects, aged 18-70 yrs. Restriction was defined as a reduced TLC. Lower limits of normal (LLN) for TLC were obtained from the European Respiratory Society recommended reference equations. Reference equations from the National Health and Nutrition Examination Survey III were used for Forced vital capacity (FVC) and Forced Expiratory Volume in six seconds (FEV(6)). The performance of FVC and FEV(6) to predict the presence of restriction was studied as follows: 1) using two-by-two (2x2) tables; and 2) by logistic regression analysis. Both analyses were performed in obstructive (defined as Forced Expiratory Volume in one second (FEV(1))/FVC or FEV(1)/FEV(6) 100% pred (males) or >85% pred (females). In obstructive patients, spirometry cannot reliably diagnose a concomitant restrictive defect, but it can rule out restriction for patients with Forced vital capacity or Forced Expiratory Volume in six seconds >85% pred (males) or >70% pred (females).
-
Forced vital capacity and Forced Expiratory Volume in six seconds as predictors of reduced total lung capacity
European Respiratory Journal, 2008Co-Authors: Jan Vandevoorde, L. Broekaert, Jan Kartounian, Dirk Devroey, Daniel Schuermans, Sylvia Verbanck, Walter VinckenAbstract:The present study aims to derive guidelines that identify patients for whom spirometry can reliably predict a reduced total lung capacity (TLC). A total of 12,693 lung function tests were analysed on Caucasian subjects, aged 18–70 yrs. Restriction was defined as a reduced TLC. Lower limits of normal (LLN) for TLC were obtained from the European Respiratory Society recommended reference equations. Reference equations from the National Health and Nutrition Examination Survey III were used for Forced vital capacity (FVC) and Forced Expiratory Volume in six seconds (FEV6). The performance of FVC and FEV6 to predict the presence of restriction was studied as follows: 1) using two-by-two (2×2) tables; and 2) by logistic regression analysis. Both analyses were performed in obstructive (defined as Forced Expiratory Volume in one second (FEV1)/FVC or FEV1/FEV6
Theodore F Reiss - One of the best experts on this subject based on the ideXlab platform.
-
montelukast a once daily leukotriene receptor antagonist in the treatment of chronic asthma a multicenter randomized double blind trial
JAMA Internal Medicine, 1998Co-Authors: Theodore F Reiss, Paul Chervinsky, Robert J Dockhorn, Sumiko Shingo, Beth C Seidenberg, Thomas B EdwardsAbstract:Objectives To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more. Design Randomized, multicenter, double-blind, placebo-controlled, parallel-group study. A 2-week, single-blind, placebo run-in period was followed by a 12-week, double-blind treatment period (montelukast sodium, 10 mg, or matching placebo, once daily at bedtime) and a 3-week, double-blind, washout period. Setting/Patients Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a Forced Expiratory Volume in 1 second 50% to 85% of the predicted value, at least a 15% improvement in Forced Expiratory Volume in 1 second (absolute value) after inhaled β-agonist administration, a minimal predefined level of daytime asthma symptoms, and inhaled β-agonist use. Twenty-three percent of the patients used concomitant inhaled corticosteroids. Primary End Points Forced Expiratory Volume in 1 second and daytime asthma symptoms. Results Montelukast improved airway obstruction (Forced Expiratory Volume in 1 second, morning and evening peak Expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" β-agonist use, nocturnal awakenings) ( P P P Conclusions Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.
-
montelukast a once daily leukotriene receptor antagonist in the treatment of chronic asthma a multicenter randomized double blind trial
JAMA Internal Medicine, 1998Co-Authors: Theodore F Reiss, Paul Chervinsky, Robert J Dockhorn, Sumiko Shingo, Beth C Seidenberg, Thomas B EdwardsAbstract:OBJECTIVES: To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more. DESIGN: Randomized, multicenter, double-blind, placebo-controlled, parallel-group study. A 2-week, single-blind, placebo run-in period was followed by a 12-week, double-blind treatment period (montelukast sodium, 10 mg, or matching placebo, once daily at bedtime) and a 3-week, double-blind, washout period. SETTING/PATIENTS: Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a Forced Expiratory Volume in 1 second 50% to 85% of the predicted value, at least a 15% improvement in Forced Expiratory Volume in 1 second (absolute value) after inhaled beta-agonist administration, a minimal predefined level of daytime asthma symptoms, and inhaled beta-agonist use. Twenty-three percent of the patients used concomitant inhaled corticosteroids. PRIMARY END POINTS: Forced Expiratory Volume in 1 second and daytime asthma symptoms. RESULTS: Montelukast improved airway obstruction (Forced Expiratory Volume in 1 second, morning and evening peak Expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" beta-agonist use, nocturnal awakenings) (P<.001 compared with placebo). Montelukast provided near-maximal effect in these end points within the first day of treatment. Tolerance and rebound worsening of asthma did not occur. Montelukast improved outcome end points, including asthma exacerbations, asthma control days (P<.001 compared with placebo), and decreased peripheral blood eosinophil counts (P<.001 compared with placebo). The incidence of adverse events and discontinuations from therapy were similar in the montelukast and placebo groups. CONCLUSIONS: Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.
Eric Garshick - One of the best experts on this subject based on the ideXlab platform.
-
determinants of Forced Expiratory Volume in 1 second fev1 Forced vital capacity fvc and fev1 fvc in chronic spinal cord injury
Archives of Physical Medicine and Rehabilitation, 2006Co-Authors: Nitin B Jain, Robert H Brown, Carlos G Tun, David R Gagnon, Eric GarshickAbstract:RESPIRATORY DYSFUNCTION IS among the most common causes of morbidity and mortality in chronic spinal cord injury (SCI).1-3 Early assessments of pulmonary function in SCI included relatively few subjects and focused mainly on the relation between level and completeness of injury and reduction in pulmonary function.4-7 Because the degree of muscle paralysis in SCI is determined by the extent of neurologic damage, the higher the neurologic level and more complete the injury, the greater is the likelihood of respiratory muscle dysfunction.8,9 More recently, investigators have begun to address factors in addition to SCI level in larger cross-sectional cohorts. In particular, the contributions of duration of injury, respiratory symptoms, and smoking have been assessed.9-12 However, the results for cigarette smoking have varied, and the contributions of other factors such as respiratory muscle strength and coexisting medical conditions to pulmonary function in SCI have not been considered in previous studies.4-13 In this article, we present the results of a cross-sectional assessment of Forced Expiratory Volume in 1 second (FEV1), Forced vital capacity (FVC), and FEV1/FVC in a large cohort of participants with SCI. We adjusted for SCI level and completeness of injury, and we examined the effects of age, pack-years of smoking, duration of injury, and respiratory symptoms (eg, wheeze). We also assessed the contributions of other factors that may influence pulmonary function but have not previously been assessed in SCI. These factors include respiratory muscle strength, body mass index (BMI), coexisting medical conditions, and previous chest injury or operations.